Skip to search form
Skip to main content
>
Semantic Scholar
Semantic Scholar's Logo
Search
Sign In
Create Free Account
You are currently offline. Some features of the site may not work correctly.
custirsen
National Institutes of Health
Create Alert
Related topics
Related topics
1 relation
Broader (1)
OGX-011
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.
K. Chi
,
C. Higano
,
+13 authors
J. D. de Bono
The Lancet. Oncology
2017
Corpus ID: 128515
BACKGROUND Clusterin is a chaperone protein associated with treatment resistance and upregulated by apoptotic stressors such as…
Expand
2017
2017
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel…
T. Beer
,
S. Hotte
,
+11 authors
K. Fizazi
The Lancet. Oncology
2017
Corpus ID: 46872049
BACKGROUND Docetaxel and cabazitaxel improve overall survival compared with mitoxantrone in patients with metastatic castration…
Expand
2017
2017
A population pharmacokinetic meta‐analysis of custirsen, an antisense oligonucleotide, in oncology patients and healthy subjects
Alena Y Z Edwards
,
Anna Elgart
,
Colm Farrell
,
Ofra Barnett-Griness
,
L. Rabinovich-Guilatt
,
O. Spiegelstein
British journal of clinical pharmacology
2017
Corpus ID: 43099370
AIMS Custirsen (OGX-011/TV-1011), a second-generation antisense oligonucleotide that reduces clusterin production, is under…
Expand
2015
2015
Phase III SYNERGY trial: Docetaxel +/- custirsen and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and poor prognosis.
K. Chi
,
C. Higano
,
+6 authors
J. Bono
2015
Corpus ID: 79427145
5009 Background: Clusterin is a chaperone protein associated with treatment resistance and upregulated by apoptotic stressors…
Expand
2015
2015
Impact of dosing regimen of custirsen, an antisense oligonucleotide, on safety, tolerability and cardiac repolarization in healthy subjects.
Laura Rabinovich‐Guilatt
,
Anna Elgart
,
+5 authors
O. Spiegelstein
British journal of clinical pharmacology
2015
Corpus ID: 26470876
AIMS Custirsen (OGX-011/TV-1011), a second-generation antisense oligonucleotide (ASO) that reduces clusterin production, is under…
Expand
2013
2013
Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen
B. Blumenstein
,
F. Saad
,
+4 authors
C. Jacobs
Cancer medicine
2013
Corpus ID: 14460829
Elevated levels of clusterin (CLU), a stress‐induced and secreted cytoprotective chaperone, are associated with advanced tumor…
Expand
Highly Cited
2012
Highly Cited
2012
Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer
J. Laskin
,
G. Nicholas
,
+12 authors
D. Hao
Journal of thoracic oncology : official…
2012
Corpus ID: 6178064
Purpose: Clusterin (CLU), an antiapoptotic, stress-associated protein, confers resistance to therapy when overexpressed. This…
Expand
Highly Cited
2011
Highly Cited
2011
Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after…
F. Saad
,
S. Hotte
,
+10 authors
E. Winquist
Clinical Cancer Research
2011
Corpus ID: 207708985
Purpose: Clusterin (CLU) is an antiapoptotic, stress-induced protein conferring treatment resistance when overexpressed. This…
Expand
2011
2011
SYNERGY: A randomized phase III study comparing first-line docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic castrate-resistant prostate cancer (mCRPC).
K. Chi
,
J. D. de Bono
,
C. Higano
Journal of clinical oncology : official journal…
2011
Corpus ID: 34873741
TPS180 Background: Custirsen (OGX-011) is a second generation antisense oligonucleotide (ASO) with a prolonged tissue half-life…
Expand
2008
2008
A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer (HRPC) who relapsed on or within six months of 1st-line docetaxel…
F. Saad
,
S. Hotte
,
+6 authors
E. Winquist
2008
Corpus ID: 74489083
5002 Background: There is no standard of care when pts with metastatic HRPC manifest disease progression (PD) after 1st-line…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE